Physician profile
David J Posey
NPI 1023055894
$2,891.15
in general payments reported to CMS, 2019-2025
16 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $57.92 · 2021: $620 · 2022: $334 · 2023: $220 · 2024: $331 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $422.80 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $383.38 | 2019-2024 | Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $364.07 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $331.94 | 2019-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $220.73 | 2023-2025 | Auvelity |
| Allergan, INC. | $213.82 | 2019 | |
| Ironshore Pharmaceuticals INC. | $167.10 | 2019-2020 | |
| Corium, LLC | $164.40 | 2021-2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $141.75 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $124.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $121.18 | 2025 | Cobenfy |
| Eisai INC. | $108.96 | 2021 | |
| Supernus Pharmaceuticals, INC. | $61.38 | 2021-2022 | |
| Lundbeck LLC | $34.87 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.66 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Posey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.